Publicacions en col·laboració amb investigadors/es de Hospital Universitario de la Princesa (18)

2024

  1. Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study

    Pain Medicine (United States), Vol. 25, Núm. 3, pp. 194-202

  2. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study

    Frontiers in Neurology , Vol. 15

  3. RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine

    European Journal of Neurology, Vol. 31, Núm. 4

2023

  1. Recomendaciones de consenso para el tratamiento de la prevención de la migraña

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. 246-253

  2. [Translated article] Consensus recommendations on the preventive treatment of migraine

    Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. T246-T253

2022

  1. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

  2. Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients

    Cephalalgia, Vol. 42, Núm. 8, pp. 804-809

2021

  1. Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown

    Neurological Sciences, Vol. 42, Núm. 12, pp. 5087-5092

  2. Evaluation of the Impact of the COVID-19 Lockdown in the Clinical Course of Migraine

    Pain medicine (Malden, Mass.), Vol. 22, Núm. 9, pp. 2079-2091

2020

  1. Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine

    Headache, Vol. 60, Núm. 1, pp. 153-161

  2. Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study

    European Journal of Neurology, Vol. 27, Núm. 10, pp. 2102-2108

  3. Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine

    Neurologia, Vol. 35, Núm. 8, pp. 568-578

2019

  1. CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA

    Journal of Headache and Pain, Vol. 20, Núm. 1

  2. Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice

    Neurologia, Vol. 34, Núm. 6, pp. 408-417

  3. Prediction of patient's response to OnabotulinumtoxinA treatment for migraine

    Heliyon, Vol. 5, Núm. 2

  4. Real world preventative drug management of migraine among Spanish neurologists

    Journal of Headache and Pain, Vol. 20, Núm. 1

  5. Wearing off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients

    Pain Medicine (United States), Vol. 20, Núm. 9, pp. 1815-1821

2018

  1. Patterns of anaesthetic pericranial nerve block in headache patients

    Neurologia, Vol. 33, Núm. 3, pp. 160-164